Details:
The financing will be used to to support OMass as it continues to progress its pipeline of small molecule therapeutics for rare diseases and immunological conditions targeting solute carriers, complex-bound proteins and GPCRs.
Lead Product(s): Undisclosed
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: British Patient Capital
Deal Size: $107.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 15, 2023
Details:
The collaboration will run over three years and will capitalise on the world-class exosome research environment in Oxford, leveraging exosome therapeutics expertise and resources from both Evox and the University to drive innovation within rare disease drug development.
Lead Product(s): Exosome-based therapeutics
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Evox Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 17, 2020